Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Chlorhexidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorhexidine SCHEMBL16177847 | 1.00 | CNR1 (0.47) | CNR1SLC6A3SMN1; SMN2HDAC8LMNA | |
| Chlorhexidine SCHEMBL2975320 | 0.99 | CNR1 (0.48) | CNR1SLC6A3SMN1; SMN2HDAC8LMNA | |
| Chlorhexidine SCHEMBL12044 | 0.99 | CNR1 (0.48) | CNR1SLC6A3SMN1; SMN2HDAC8LMNA | |
| Chlorhexidine SCHEMBL2975314 | 0.99 | CNR1 (0.48) | CNR1SLC6A3SMN1; SMN2HDAC8LMNA | |
| Chlorhexidine SCHEMBL12043 | 0.99 | CNR1 (0.48) | CNR1SLC6A3SMN1; SMN2HDAC8LMNA | |
| Chlorhexidine SCHEMBL3192051 | 0.97 | CNR1 (0.47) | CNR1SLC6A3SMN1; SMN2HDAC8LMNA | |
| Chlorhexidine SCHEMBL6377040 | 0.97 | CNR1 (0.47) | CNR1SLC6A3SMN1; SMN2HDAC8LMNA | |
| Chlorhexidine SCHEMBL17967106 | 0.97 | CNR1 (0.47) | CNR1SLC6A3SMN1; SMN2HDAC8LMNA | |
| Chlorhexidine SCHEMBL2152513 | 0.97 | CNR1 (0.47) | CNR1SLC6A3SMN1; SMN2HDAC8LMNA | |
| Chlorhexidine SCHEMBL2152457 | 0.94 | CNR1 (0.47) | CNR1SLC6A3SMN1; SMN2HDAC8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315869-A1 | THERAPEUTIC USES OF ECTOINE | BITOP AG (DE) | 2014-10-23 | — | — | US | disclosed |
| US-7022687-B1 | Combination of loteprednol and antihistamines | ASTA MEDICA AG (DE) | 2006-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315869-A1 | THERAPEUTIC USES OF ECTOINE | ELANE, MMP8, TNF | CNR1 3314/4885SLC6A3 3528/4885SMN1; SMN2 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.